Valuation: Insmed Incorporated

Capitalization 25.14B 21.47B 19.67B 18.6B 34.44B 2,406B 34.62B 234B 91.2B 1,142B 94.34B 92.36B 3,969B P/E ratio 2026 *
-42.8x
P/E ratio 2027 * 156x
Enterprise value 24.54B 20.96B 19.2B 18.15B 33.62B 2,349B 33.79B 229B 89.01B 1,115B 92.08B 90.15B 3,874B EV / Sales 2026 *
14.4x
EV / Sales 2027 * 8.63x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day+1.54%
1 week-13.65%
Current month-13.17%
1 month-21.68%
3 months-20.42%
6 months-38.01%
Current year-31.98%
1 week 98.9
Extreme 98.9
125.36
1 month 98.9
Extreme 98.9
154.58
Current year 98.9
Extreme 98.9
186.19
1 year 64.84
Extreme 64.845
212.75
3 years 18.08
Extreme 18.085
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 9.02
Extreme 9.02
212.75
Manager TitleAgeSince
Chief Executive Officer 57 09/09/2012
Director of Finance/CFO 45 30/01/2020
Chief Tech/Sci/R&D Officer 62 18/12/2019
Director TitleAgeSince
Chairman 75 15/06/2009
Chairman 57 07/11/2018
Director/Board Member 71 29/10/2013
Change 5d. change 1-year change 3-years change Capi.($)
+1.16%-13.65%+80.15%+514.30% 25.14B
-1.58%-0.17%+40.62%+83.11% 50.91B
-1.28%-0.58%+83.34%+64.48% 49.21B
-1.27%-2.94%-2.16%-14.31% 23.69B
+0.47%+0.06%+45.63%-26.47% 17.81B
-1.66%-4.83%+32.60%-41.59% 16.5B
-2.08%-0.39%+60.13%+199.18% 15.3B
-0.77%+5.66%-23.36%+930.60% 14.71B
-1.82%-0.96%+47.46% - 13.73B
+3.17%+4.62%+37.89%+161.28% 12.43B
Average -0.53%+0.23%+40.23%+207.84% 23.94B
Weighted average by Cap. -0.76%-0.66%+46.71%+166.50%

Financials

2026 *2027 *
Net sales 1.7B 1.45B 1.33B 1.26B 2.33B 163B 2.34B 15.83B 6.16B 77.17B 6.38B 6.24B 268B 2.76B 2.36B 2.16B 2.04B 3.78B 264B 3.8B 25.72B 10.01B 125B 10.36B 10.14B 436B
Net income -572M -488M -447M -423M -783M -54.73B -787M -5.33B -2.07B -25.97B -2.15B -2.1B -90.27B 99.75M 85.19M 78.05M 73.79M 137M 9.55B 137M 929M 362M 4.53B 374M 366M 15.75B
Net Debt -603M -515M -472M -446M -826M -57.68B -830M -5.62B -2.19B -27.37B -2.26B -2.21B -95.14B -1.03B -877M -803M -760M -1.41B -98.27B -1.41B -9.57B -3.72B -46.63B -3.85B -3.77B -162B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
13/05/26 117.15 $ +0.99% 4,970,275
12/05/26 116.00 $ +11.66% 8,274,773
11/05/26 103.89 $ +2.51% 7,898,445
08/05/26 101.35 $ -3.48% 8,588,262
07/05/26 105.00 $ -23.41% 13,718,250
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
116.00USD
Average target price
203.30USD
Spread / Average Target
+75.26%

Quarterly revenue - Rate of surprise